Clinical Trials Logo

Toripalimab clinical trials

View clinical trials related to Toripalimab.

Filter by:
  • None
  • Page 1

NCT ID: NCT05760053 Recruiting - Clinical trials for First-line Treatment

Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma

Start date: February 18, 2023
Phase: Phase 2
Study type: Interventional

This study is a prospective, multicenter, open-label, single-arm phase II clinical trial. A single-arm experimental group of toripalimab, etoposide, and cisplatin/carboplatin was designed to evaluate its efficacy and safety in small cell carcinoma of the urinary system.

NCT ID: NCT05669092 Recruiting - Radiation Clinical Trials

A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status

Start date: November 1, 2022
Phase: Phase 3
Study type: Interventional

pMMR/MSS and 32 dMMR/MSI-H patientspatients were planned to be enrolled. Patients with dMMR/MSI-H will be randomly assigned to the immunotherapy arm or short-course radiotherapy sequential immunotherapy arm; pMMR/MSS patients will receive capecitabine-irinotecan based concurrent radiotherapy before being randomly assigned to the XELIRI or FOLFRINOX arm. The rate of complete response (sustained cCR for ≥ 1 year), long-term prognosis and adverse effects will be analyzed.

NCT ID: NCT04992988 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

Start date: June 28, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, phase II trial to study the efficacy of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy in treating patients with locoregionally recurrent nasopharyngeal carcinoma.

NCT ID: NCT04709380 Recruiting - Radiotherapy Clinical Trials

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

Start date: March 2, 2021
Phase: Phase 3
Study type: Interventional

To explore the efficacy of radiotherapy plus toripalimab Versus standard treatment of sorafenib in advanced hepatocellular carcinoma with Portal Vein/Hepatic vein Tumor Thrombosis.

NCT ID: NCT04627363 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm clinical study to preliminarily observe and evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin synchronous combined with Bevacizumab and Toripalimab as the first-line therapy for advanced HCC.

NCT ID: NCT04425824 Not yet recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Start date: June 15, 2020
Phase: Phase 2
Study type: Interventional

Exploring the efficacy and safety of Toripalimab with Rituximab for treatment of relapsed refractory CD20 positive diffuse large B-cell lymphoma.

NCT ID: NCT04278222 Recruiting - Gastric Cancer Clinical Trials

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE)

Start date: February 10, 2020
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy and safety of the combination of Anlotinib wiht Toripalimab in advanced gastric or gastro-oesophageal junction cancer as first-line treatment.